A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database (IMPACT MASH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
-
Bangalore, India
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For All and Study population:
- Male or female, age above or equal to 18 years on health-check-up visit day
- No missing value on sex
For EASL at risk population
- Must be part of study population.
- People with T2D or [obesity+above or equal to 1 cardiometabolic risk factor(s)] or elevated liver enzymes
For EASL not at-risk population
1. Must be part of study population.
For EASL-SAFE
- Must be part of EASL at risk population
For AGA at risk population
- Must be part of study population.
- People with 2 or more metabolic risk factors (EASL-MASLD criteria) or T2D or steatosis on any imaging modality or with elevated aminotransferases
For CSH MAFLD population
- Must be part of study population.
- Liver steatosis on abdominal ultrasound
- With at least one component of Metabolic syndrome (MetS [CSH])
Exclusion Criteria:
- Individuals originating from centers with fewer than 100 participants
- Missing value of liver stiffness measurement (LSM)
- Had an interquartile range/median ratio above or equal to 30% of the measurement of LSM
- Missing value on either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or platelet count (PLT)
- Missing value on FPG, TG, HDLc or BP (to define the presence of metabolic risk factors)
- Missing value on abdominal ultrasound
For EASL not at-risk population 1. People with T2D or [obesity+above or equal to 1 cardiometabolic risk factor(s)] or elevated liver enzymes
For EASL-SAFE/NFS
1. Missing value on globulin
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort
People who underwent health check-up in Meinian check-up centres between the period January 1st, 2023, to December 31st, 2023
|
No treatment given
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
Time Frame: January 1st, 2023, to December 31st, 2023
|
Number and proportion of people in respective risk population
|
January 1st, 2023, to December 31st, 2023
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DAS-8256
- U1111-1308-1064 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.